• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Nkarta Inc. (Amendment)

    3/28/24 7:25:26 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    SC 13D/A 1 nea15-nkarta_18816.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / NKARTA, INC. -- SCHEDULE 13D/A(#2) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Nkarta, Inc.

    (Name of Issuer)

    Common Stock, $.0001 par value

    (Title of Class of Securities)

    65487U108

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    March 27, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 65487U108

    13D Page 2 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 15, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 65487U108

    13D Page 3 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 15, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

      

     

     

     

     CUSIP No. 65487U108

    13D Page 4 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    NEA 15 GP, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

     

      CUSIP No. 65487U108

    13D Page 5 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 65487U108

    13D Page 6 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 65487U108

    13D Page 7 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

        3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 65487U108

    13D Page 8 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7

     

    SOLE VOTING POWER

     

    0 Shares

     

      8  

    SHARED VOTING POWER

     

    3,568,781 Shares

     

      9  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10  

    SHARED DISPOSITIVE POWER

     

    3,568,781 Shares

     

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,568,781 Shares

     

       
    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    5.1%

     

       

     14

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 65487U108

    13D Page 9 of 16 Pages    

     

    Item 1.  Security and Issuer.

    This Amendment No. 2 (“Amendment No. 2”) to Schedule 13D amends and restates the statement on Schedule 13D originally filed on July 23, 2020 and Amendment No. 1 thereto filed on May 5, 2022, relating to the common stock, $0.0001 par value (the “Common Stock”) of Nkarta, Inc. (the “Issuer”) having its principal executive office at 6000 Shoreline Court, Suite 102, South San Francisco, California 94080.

     

    Certain terms used but defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 thereto). 

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 15, L.P. (“NEA 15”), NEA Partners 15, L.P. (“NEA Partners 15”), which is the sole general partner of NEA 15; and NEA 15 GP, LLC (“NEA 15 LLC” and, together with NEA Partners 15, the “Control Entities”), which is the sole general partner of NEA Partners 15; and

     

    (c) Forest Baskett (“Baskett”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”) and Scott D. Sandell (“Sandell”) (together, the “Managers”) and Peter W. Sonsini (“Sonsini”). The Managers are the managers of NEA 15 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 Fifth Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 15 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

     

     

     

     

    CUSIP No. 65487U108

    13D Page 10 of 16 Pages    

     

     

     

    Item 5.  Interest in Securities of the Issuer.

    NEA 15 is the record owner of the NEA 15 Shares. As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares.

     

    Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares other than those shares which such person owns of record.

     

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 70,191,295 shares of Common Stock reported to be outstanding immediately following the Offering on the Issuer’s prospectus supplement filed under Rule 424(b)(5), filed with the Securities and Exchange Commission on March 26, 2024.

     

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)

    None of the Reporting Persons has effected any transaction in the NEA 15 Shares during the last 60 days.

     

    (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, NEA 15 Shares beneficially owned by any of the Reporting Persons.

     

    (e)

    Sonsini has ceased to beneficially own 5% or more of the Issuer’s Common Stock as a result of ceasing to be a manager of NEA 15 LLC.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

    Item 7.  Material to Be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

    CUSIP No. 65487U108

    13D Page 11 of 16 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 28th day of March, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:   /s/ Stephanie Brecher         

     Stephanie Brecher

     General Counsel 

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:   /s/ Stephanie Brecher       

    Stephanie Brecher

    General Counsel 

     

      

     

     

    NEA 15 GP, LLC

     

    By:   /s/ Stephanie Brecher       

    Stephanie Brecher

    General Counsel 

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 65487U108

    13D Page 12 of 16 Pages    

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

     

     

    This Amendment No. 2 to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     
     

     

    CUSIP No. 65487U108

    13D Page 13 of 16 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Nkarta, Inc.

     

    EXECUTED this 28th day of March, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 15, L.P.

     

    By:

    NEA PARTNERS 15, L.P.

    General Partner

     

    By:

    NEA 15 GP, LLC

    General Partner

      

      By:   /s/ Stephanie Brecher         

     Stephanie Brecher

     General Counsel 

     

     

    NEA PARTNERS 15, L.P.

     

    By:NEA 15 GP, LLC
    General Partner

     

    By:   /s/ Stephanie Brecher       

    Stephanie Brecher

    General Counsel 

     

     

     

      

    NEA 15 GP, LLC

     

    By:   /s/ Stephanie Brecher       

    Stephanie Brecher

    General Counsel 

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 65487U108

    13D Page 14 of 16 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

     

     

     

     

     

    */s/ Stephanie Brecher           

    Stephanie Brecher

    As attorney-in-fact

     

     

    This Agreement relating to Schedule 13D was executed by Stephanie Brecher on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

    CUSIP No. 65487U108

    13D Page 15 of 16 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 65487U108

    13D Page 16 of 16 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

      

    Get the next $NKTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    3/11/2022$17.00Outperform
    Raymond James
    More analyst ratings

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nkarta to Participate in an April Investor Conference

      SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu

      4/1/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWI

      3/26/25 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Participate in March Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the

      2/25/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Nkarta Inc.

      DEFA14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:20:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nkarta Inc.

      DEF 14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:19:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Nkarta Inc.

      10-K - Nkarta, Inc. (0001787400) (Filer)

      3/26/25 4:20:11 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/29/24 5:38:04 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/28/24 4:30:06 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nkarta Inc.

      SC 13G - Nkarta, Inc. (0001787400) (Subject)

      12/13/24 5:02:47 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 4:05:12 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 8:55:31 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Shook David sold $19,004 worth of shares (8,638 units at $2.20), decreasing direct ownership by 4% to 190,955 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:37:19 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Levin Alyssa sold $12,844 worth of shares (5,838 units at $2.20), decreasing direct ownership by 5% to 102,662 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:57 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Brandenberger Ralph sold $16,383 worth of shares (7,447 units at $2.20), decreasing direct ownership by 6% to 124,796 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:35 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

      SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

      7/16/24 6:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

      NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2

      8/10/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Nkarta with a new price target

      Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

      10/9/24 7:55:21 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta upgraded by Raymond James with a new price target

      Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

      8/14/24 7:45:34 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta downgraded by Raymond James with a new price target

      Raymond James downgraded Nkarta from Strong Buy to Outperform and set a new price target of $16.00 from $13.00 previously

      3/22/24 7:49:46 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Financials

    Live finance-specific insights

    See more
    • Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

      New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

      10/17/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

      10/16/23 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

      Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

      6/27/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care